BRTX
HEALTHCAREBioRestorative Therapies Inc
AI Insight
What's Moving BRTX Today?
No stock-specific AI insight has been generated for BRTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.16$1.89
$0.40
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.06
Dividend Yield—
Dividend / Share—
ROE-241.1%
Profit Margin—
Debt / Equity—
Trading
Volume276K
Avg Volume (10D)—
Shares Outstanding25.5M
BRTX News
23 articles- BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic GrowthYahoo Finance·Jun 18, 2026
- BioRestorative Therapies extends employment agreements for Lance Alstodt and Robert KristalTradingView·May 30, 2026
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)Yahoo Finance·May 27, 2026
- Sector Update: Healthcare Stocks Decline Tuesday AfternoonYahoo Finance·May 26, 2026
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataYahoo Finance·May 26, 2026
- What Makes Biorestorative Therapies (BRTX) a New Buy StockYahoo Finance·May 15, 2026
- BioRestorative Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTradingView·May 15, 2026
- Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 14, 2026
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsYahoo Finance·May 13, 2026
- Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 11, 2026
- PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease – Ortho Spine NewsOrtho Spine News·May 7, 2026
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseYahoo Finance·May 7, 2026
- Geron (GERN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformYahoo Finance·Apr 30, 2026
- Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom FishingYahoo Finance·Apr 27, 2026
- BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformYahoo Finance·Apr 21, 2026
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformYahoo Finance·Apr 7, 2026
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseYahoo Finance·Mar 30, 2026
- Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag EstimatesYahoo Finance·Mar 19, 2026
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseYahoo Finance·Mar 19, 2026
All 23 articles loaded
Price Data
Open$0.38
Previous Close$0.38
Day High$0.40
Day Low$0.38
52 Week High$1.89
52 Week Low$0.16
52-Week Range
$0.16$1.89
$0.40
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.06
Dividend Yield—
Dividend / Share—
ROE-241.1%
Profit Margin—
Debt / Equity—
Trading
Volume276K
Avg Volume (10D)—
Shares Outstanding25.5M
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols that primarily involve adult stem cells. The company is headquartered in Melville, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—